Please use this identifier to cite or link to this item: http://dspace.iitrpr.ac.in:8080/xmlui/handle/123456789/2717
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGoyal, K.-
dc.contributor.authorKoul, V.-
dc.contributor.authorSingh, Y.-
dc.contributor.authorAnand, A.-
dc.date.accessioned2021-09-20T06:28:31Z-
dc.date.available2021-09-20T06:28:31Z-
dc.date.issued2021-09-20-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/2717-
dc.description.abstractThe treatment of brain diseases has been a major challenge since a long time. Although there are several potent drugs, which are highly therapeutic yet their efficiency is marred due to the presence of the Blood Brain Barrier (BBB). The BBB, which is present at the capillary level regulates and monitors the entry of all small and large molecules entering into the brain. Although this barrier is of immense importance to the brain in terms of safety, it becomes a hindrance when it comes to therapy because the drug molecules are unable to reach the brain. Various biomaterial-based strategies are being developed to overcome the BBB and deliver the drug into the brain. These include polymeric nanoparticles, liposomes, solid-lipid nanoparticles (SLNPs), nanogels, implants, etc. This review provides an overview on CNS disorders, BBB, and various delivery strategies available for biologists engaged in translational neuroscience, to target CNS.en_US
dc.language.isoen_USen_US
dc.subjectBlood-brain barrier (BBB)en_US
dc.subjectCNS drug deliveryen_US
dc.subjectdrug transporten_US
dc.subjecttargetingen_US
dc.titleTargeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advancesen_US
dc.typeArticleen_US
Appears in Collections:Year-2014

Files in This Item:
File Description SizeFormat 
Full Text.pdf564.03 kBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.